Magnus Financial Group LLC Takes Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Magnus Financial Group LLC acquired a new position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 24,000 shares of the company’s stock, valued at approximately $55,000.

Other institutional investors have also recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. boosted its stake in shares of Checkpoint Therapeutics by 9.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock valued at $84,000 after buying an additional 4,205 shares during the period. Sabby Management LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter worth $349,000. Armistice Capital LLC raised its stake in Checkpoint Therapeutics by 46.1% in the third quarter. Armistice Capital LLC now owns 2,064,000 shares of the company’s stock valued at $3,509,000 after purchasing an additional 651,000 shares in the last quarter. Legacy Wealth Asset Management LLC grew its stake in Checkpoint Therapeutics by 104.8% during the third quarter. Legacy Wealth Asset Management LLC now owns 85,000 shares of the company’s stock worth $144,000 after buying an additional 43,500 shares in the last quarter. Finally, PVG Asset Management Corp increased its holdings in Checkpoint Therapeutics by 81.9% in the 3rd quarter. PVG Asset Management Corp now owns 111,025 shares of the company’s stock valued at $189,000 after buying an additional 50,000 shares during the period. Institutional investors own 22.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Checkpoint Therapeutics in a research note on Friday, March 22nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $22.60.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT opened at $1.44 on Tuesday. Checkpoint Therapeutics, Inc. has a twelve month low of $1.30 and a twelve month high of $3.62. The business’s fifty day moving average is $1.90 and its 200 day moving average is $2.05.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Friday, March 22nd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.36). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.09 million. Equities research analysts forecast that Checkpoint Therapeutics, Inc. will post -1.34 EPS for the current year.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.